NIH BILL: SENATE OVERRIDES VETO OF BIOMEDICAL RESEARCH
Executive Summary
NIH BILL: SENATE OVERRIDES VETO OF BIOMEDICAL RESEARCH reauthorization bill (HR 2409) by a vote of 89-7. The Senate action, which occurred on Nov. 20, paves the way for the measure's adoption as law. The House, on Nov. 12, voted 380-32 to override President Reagan's Nov. 8 veto of the bill. A two-thirds majority is required in both houses of Congress to enact an override. HR 2409 establishes an arthritis institute and a nursing research center at the Natl. Institutes of Health. The president's veto message opposed the nursing center but endorsed the creation of an arthritis institute, albeit, under an administrative action by HHS. The administration's chief complaint with the bill has been over the detailed administrative and program requirements it places on NIH, including restrictions on fetal and animal research and new requirements for peer review. HR 2409 exerts "undue political control over decisions regarding scientific research, thus limiting the ability of the NIH to set this nation's biomedical research agenda," Reagan said in his veto statement. The president vetoed a nearly identical NIH reauthorization bill last year, but Congress did not muster the votes to override the decision. HR 2409 contains $2.4 bil. in biomedical research authorities for fiscal 1986, with slightly higher amounts approved for both fiscal 1987 and 1988.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth